Lilly Strikes $1.3 Billion GPCR Drug Discovery Pact with Superluminal
Key Points: 1. Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2. Superluminal’s lead melanocortin 4 receptor candidate is expected to enter human trials next year. On August 14, 2025, Eli Lilly announced a strategic collaboration with Superluminal Medicines valued at up to $1.3 billion to […]
The post Lilly Strikes $1.3 Billion GPCR Drug Discovery Pact with Superluminal first appeared on 2 Minute Medicine.Source: 2 Minute Medicine